Clinical Trial Update: A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial update describes GR1803 Injection combined with an anti-CD38 monoclonal antibody for treating multiple myeloma, which is not ye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Anti-CD38 monoclonal antibody (CD38-directed monoclonal antibody)
• GR1803 Injection (GR1803)

Snippet

Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING